Last reviewed · How we verify
STP707
At a glance
| Generic name | STP707 |
|---|---|
| Also known as | STP707 Powder for Injection |
| Sponsor | Sirnaomics |
| Modality | Small molecule |
| Phase | Phase 1 |
Approved indications
Common side effects
Key clinical trials
- Ph. 1, Evaluation of Safety, Tolerability, PK, Anti-tumor Activity of STP707 IV in Subjects With Solid Tumors (PHASE1)
- A Study of STP707 Administered by IV in Healthy Subjects (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- STP707 CI brief — competitive landscape report
- STP707 updates RSS · CI watch RSS
- Sirnaomics portfolio CI